{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Source:
NCT01550406: Phase 4 Interventional Completed Pancreatic Fistula
(2011)
Source URL:
First approved in 2014
Source:
21 CFR 352
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
M020
(2017)
Source URL:
First approved in 2014
Source:
21 CFR 352
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
21 CFR 348
(2021)
Source URL:
First approved in 2014
Source:
21 CFR 352
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2014)
Source URL:
First approved in 2014
Source:
21 CFR 352
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2014)
Source URL:
First approved in 2014
Source:
21 CFR 352
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2017)
Source URL:
First approved in 2014
Source:
505G(a)(3)
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
505G(a)(3)
(2014)
Source URL:
First approved in 2014
Source:
505G(a)(3)
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2014)
Source URL:
First approved in 2014
Source:
21 CFR 352
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
K960428
(2014)
Source URL:
First approved in 2014
Source:
K960428
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
K960428
(2014)
Source URL:
First approved in 2014
Source:
21 CFR 347
Source URL:
Class:
POLYMER
Acemannan, an acetylated polymannose from Aloe vera, has immunomodulatory effects. Acemannan induces IL-6/-8 expression, and p50/DNA binding in gingival fibroblasts, at least partly, via a TLR5/NF-κB-dependent signaling pathway. Acemannan selectively binds with TLR5 ectodomain flagellin recognition sites. Acemannan has various medicinal properties like osteogenic, anti-inflammatory, and antibacterial, which accelerate healing of lesions. Also, acemannan is known to have antiviral and antitumor activities in vivo through activation of immune responses. It was concluded that Aloe vera has immense potential as a therapeutic agent. Acemannan induces tissue repair. Acemannan promoted skin wound healing partly through activating AKT/mTOR-mediated protein translation mechanism, which may represent an alternative therapy approach for cutaneous wound. Many research groups have demonstrated the role of
acemannan in dentistry. Acemannan can be used for the treatment of oral aphthous ulceration in patients who wish to avoid the use of steroid medication. Acemannan is an effective natural bioactive substance that promotes bone
growth, increases bone surface, bone volume and bone density.